Literature DB >> 3230151

Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension.

P K Zachariah1, C Shub, S G Sheps, A Schirger, M K Wolf, C A Carlson.   

Abstract

Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil. The mean P-R interval in 22 patients taking placebo and immediate-release verapamil was 0.18 second. The borderline first-degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P-R interval longer than 0.20 second and of those with a P-R interval of 0.20 second or less were 169 +/- 73 ng/mL and 63 +/- 8 ng/mL, respectively. Six patients taking sustained-release verapamil had a maximal mean P-R interval of 0.19 +/- 0.01 second during 24-hour ambulatory electrocardiographic monitoring. P-R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P-R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P-R interval, developed high-grade atrioventricular block.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3230151     DOI: 10.1002/j.1552-4604.1988.tb03226.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus.

Authors:  M Busch Sørensen; H Sjøstrand; H Sengeløv; M Tiefenthal Thrane; J Juul Holst; J Lyngsøe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Transgenic mice over-expressing ET-1 in the endothelial cells develop systemic hypertension with altered vascular reactivity.

Authors:  Justin Wai-Chung Leung; Wing Tak Wong; Hon Wai Koon; Fong Ming Mo; Sidney Tam; Yu Huang; Paul M Vanhoutte; Stephen Sum Man Chung; Sookja Kim Chung
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.